Top Quality Powder Nsi-189 CAS 1270138-40-3 for Memory Enhancement and Depressive Disorder Treatment

Product Name: NSI-189

Product Details:

Describtion :

NSI-189 is a benzylphiperizine-aminiopyridine, nootropic and neurogenic research chemical created by Neuralstem, Inc. that was derived from pyrazine and nicotinamide. Studies have shown that it stimulates neurogenesis of human hippocampus-derived neural stem cells in vivo and vitro . In healthy adult mice, NSI-189 has been shown to increase the hippocampal volume by 20% and reverse behavioral symptoms in mouse depression models, meaning at the source it could address depression . The hippocampus is responsible for spatial navigation, along with the consolidation of information from short-term memory to long-term memory. The chemical entity stimulates new neuron growth in the hippocampus, which is an area of the brain that is believed to be contributory in conditions such as post-traumatic stress disorder (PTSD), Alzheimer's disease, and major depressive disorder (MDD).

NSI-189 is an experimental, novel potential antidepressant that is under investigation byNeuralstem, Inc. for the treatment for major depressive disorder (MDD), as well as for cognitive impairment and neurodegeneration. Research into NSI-189 has been funded by theDefense Advanced Research Projects Agency (DARPA) and the National Institutes of Health(NIH).The mechanism of action of NSI-189 appears to be activation of neurogenesis in thehippocampus and possible enlargement of this structure, but how the drug mediates these effects is unknown and binding studies have so far failed to identify any certain molecular targets for the drug. As stated by Neuralstem, NSI-189 is a "new chemical entity with [a] novel mechanism of action, molecular target yet unknown, but not mediated by SSRI or SNRIor by BDNF release or via any known GPCRs, kinases, or channels." The drug was discovered via high-throughput screening of a library of 10,269 compounds for neurogenic effects in vitro.

NSI-189 is neurogenic and nootropic research agent that was developed from nicotinamide and pyrazine. Randomized controlled trials have shown that it stimulates neurogenesis or neuronal cell production in the brain. In animal studies, it has also been shown to increase the volume of hippocampus by 20% thereby reversing behavioral symptoms of depression. Such studies have shown that it may be an effective treatment for depression. It is also thought to be a promising treatment for other condition including post-traumatic stress disorder (PTSD), Alzheimer's disease and age-related cognitive problems. NSI-189 has been proved that is thought to potentially promote increased neuronal production whilst treat depression is NSI-189. This article discusses NSI-189 and how this novel nootropic agent can revolutionize the treatment for depression, and possibly other neurodegenerative disorders. Current treatments for major depressive disorder (MDD) mostly include the use of oral medications to modulate critical neurotransmitters in the brain. Selective serotonin reuptake inhibitors (SSRIs) are believed to be the most commonly and widely prescribed treatment for depression. Most recent research however reveals that there is a new theory regarding the cause of major depressive disorder. This theory implicates that brain physiology also influences depression rather than brain chemistry problems alone. Researchers have discovered that the disease leads to decreased hippocampal volume. Note that a healthy hippocampus is an excellent source of neural stem cells which lead to the production of neurons. Neurons on the other hand are critical for creating essential new connections in the brain. Through the production of new neurons in the hippocampal area, depression can be treated.

COA:

Function:

1) Enhance cognition and memory formation.
2) Anxiolytic properties.
3) Anti-depressive effect .
4) Treatment of Alzheimer's and Parkinson's disease.
5) Increase coordination.
6) Improves mood.
7) Help fight fatigue.
8) Prevent oxidation within the brain.
9) Treat alcohol related brain damage.

Benefits:

NSI-189 significantly improved behavioral responses that are associated with depression. In humans it may counter hippocampal atrophy which is seen in disorders such as MDD, reversing their symptoms. A phase 1B randomized, double-blind, placebo-controlled, multiple-dose escalation study conducted over a 28 day period showed behavioral efficacy in 24 patients who were orally administered NSI-189. The efficacy measurements showed a clinically meaningful reduction in cognitive and depressive symptoms across all measures, and appeared to persist over time during follow up for the efficacy assessments which included the Clinical Global Impression - Improvement (CGI-I), Montgomery-Aserb Depression Rating Scale (MADRS), Cognitive and Physical Functioning Questionnaire (CPFQ, and the Symptoms of Depression Questionnaire (SDQ).

Our Company Advantages: